Skip to main content
Figure 3 | Cost Effectiveness and Resource Allocation

Figure 3

From: Surrogate outcomes: experiences at the Common Drug Review

Figure 3

Comparison of international agencies: concerns with surrogate outcomes. Y axis: Drug submission. X axis: Agency. *No: no (e2) = implicit no “evidence 2”; no (ref) = implicit no “reference”; no (e) = explicit no “evidence 1”; no (e1 + e2) = explicit no “evidence 1” and implicit no “evidence 2”; Yes: yes (e1) = implicit yes “evidence 1”; yes (e2) = implicit yes “evidence 2”; yes (used) = implicit yes “used before”; yes (ref) = implicit yes “reference”; yes (e) = explicit yes; Not identified: N/S = no statement; N/A = not applicable; Red shades = negative statements of surrogate acceptability; Green shade = positive statement of surrogate acceptability; HbA1c = hemoglobin A1c; 6MWD = 6 minute walk distance; composite = histology, virology, serology; SVR = sustained virological response; CDR = Common Drug Review; HC = Health Canada; FDA = Food and Drug Administration; EMA = European Medicines Agency; NICE = National Institute for Health and Clinical Excellence; PBS = Pharmaceutical Benefit Scheme; SMC = Scottish Medicines Consortium.

Back to article page